Risk Of Developing Liver Cancer After HCV Treatment

Friday, April 24, 2015

EASL 2015: Link to daily updates, slide presentations, video highlights and commentary


Conference Reports:

The International Liver Congress™ 2015 
Updated Daily - Indexed by pharmaceutical company
Check out daily updates from the 2015 International Liver Congress linked by pharmaceutical company on our conference page.

View slide presentations, video highlights and commentary on key presentations including; Gilead's' sofosbuvir (Sovaldi) and sofosbuvir/ledipasvir (Harvoni) plus their three-drug regimen of Sofosbuvir, GS-5816 and GS-9857, AbbVie's Viekira Pak, Johnson & Johnson (Janssen's) simeprevir (Olysio), Bristol-Myers Squibb's daclatasvir (Daklinza), and Merck's grazoprevir/elbasvir. In addition, research in other areas include; fatty liver disease, Non-invasive markers of liver disease, complications such as cirrhosis, liver cancer, liver transplantation and therapies for hepatitis B.

Website
The International Liver Congress™ 2015 
Blog
Media Updates

No comments:

Post a Comment